

Haematologica  
HAEMATOL/2016/152900  
Version 3

ECIL-6 guidelines for the treatment of invasive candidiasis,  
aspergillosis and mucormycosis in leukemia and hematopoietic stem  
cell transplant patients

Frederic Tissot, Samir Agrawal, Livio Pagano, Georgios Petrikkos,  
Andreas H. Groll, Anna Skiada, Cornelia Lass-Flörl, Thierry Calandra,  
Claudio Viscoli, and Raoul Herbrecht

Disclosures: The ECIL meeting has been supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck Sharp Dohme, Pfizer, and Basilea FT: has received travel grants from Gilead, MSD, Viiv; has been a consultant to Astellas. LP: has received grants from Basilea, Gilead, MSD, Pfizer, Janssen; is a consultant to Basilea, Gilead, MSD, Pfizer; and served at the speakers' bureau of Astellas, Gilead, Merck/Schering and Pfizer. AHG: has received grants from Gilead, Merck, Sharp & Dohme and Pfizer; is a consultant to Amplyx, Astellas, Basilea, Gilead, Merck, and Sharp & Dohme, and served at the speakers' bureau of Astellas, Basilea, Gilead, Merck, Sharp & Dohme, Pfizer, Schering-Plough and Zeneus/Cephalon AS: has received travel grants from Gilead, MSD, Pfizer. CLF: received grants from Pfizer Gilead, Astellas, Basilea and Merck. She has been a consultant to Pfizer, Astellas, Basilea and Merck and received speaker's fees from Pfizer, Merck, Gilead and Basilea. TC: has received grants from Merck, Pfizer; is consultant to Gilead, Merck, Novartis, Pfizer, Roche, Astra Zeneca; and served at the speakers' bureau of Gilead, Merck, Pfizer. CV: has received personal fees from MSD, Gilead, Forrest Italia, Angelini, Pfizer RH: has received grants, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Gilead, personal fees from Astellas, personal fees and non-financial support from MSD, personal fees from Schering- Plough .

Contributions: FT, AS and RH reviewed the literature before the meeting FT, SA, LP, GP, AHG, AS, CLF, TC, CV and RH discussed and prepared the guidelines that were latter approved by the ECIL-5 and ECIL-6 assembly RH wrote the manuscript. FT, SA, LP, GP, AHG, AS, CLF, TC and CV reviewed the manuscript.